Literature DB >> 13899372

A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma.

N GOCHMAN, C L GANTT.   

Abstract

Entities:  

Keywords:  ALDOSTERONE/antagonists; FLUORESCENCE; LACTONES/metabolism

Mesh：

Substances：

Year:  1962        PMID： 13899372

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN： 0022-3565            Impact factor:   4.030


× No keyword cloud information.
  21 in total

1.  Plasma uric acid and spironolactone response in healthy subjects.

Authors:  L E Ramsay; J R Shelton; I R Harrison
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

2.  Canrenone--the principal active metabolite of spironolactone?

Authors:  L E Ramsay; J R Shelton; D Wilkinson; M J Tidd
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

3.  [Relative bioavailability in man of 2 pharmaceutical forms of canrenone].

Authors:  F Bressolle; J Bres; A Faure; M C Pistre
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Jul-Sep       Impact factor: 2.441

4.  Extrarenal effects of aldosterone antagonists in guinea pigs. I. Enhanced transport of potassium into the cells.

Authors:  H R Mattern; W Schaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

5.  On the mechanism of the inhibitory action of the spirolactone SC 9376 (aldadiene) on the production of corticosteroids in rat adrenals in vitro.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

6.  Inhibition of aldosterone production in diuretic-induced hyperaldosteronism by aldosterone antagonist canrenone in man.

Authors:  H C Erbler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

7.  Improved method for comparative evaluation of aldosterone antagonists in healthy man.

Authors:  J Casals-Stenzel; J Schmalbach; W Losert
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

8.  Spironolactone dose-response relationships in healthy subjects.

Authors:  G T McInnes; R M Perkins; J R Shelton; I R Harrison
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

9.  Improved bioavailability from a spironolactone beta-cyclodextrin complex.

Authors:  N T Yusuff; P York; H Chrystyn; P N Bramley; R D Swallow; B R Tuladhar; M S Losowsky
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone.

Authors:  D Levine; L Ramsay; R Auty; R Branch; M Tidd
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.